- Champion-Platform trial2010 | First Faculty of Medicine
- Intravenous Platelet Blockade with Cangrelor during PCI2009 | Third Faculty of Medicine
- New antiplatelet drugs in therapy of cardiovascular diseases2009 | First Faculty of Medicine, Third Faculty of Medicine
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events2013 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Safety and Efficacy of Cangrelor, an Intravenous, Short-Acting Platelet Inhibitor in Patients Requiring Coronary Artery Bypass Surgery2013 | Publication without faculty affiliation
- Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention2017 | Publication without faculty affiliation
- Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial2012 | Publication without faculty affiliation
- Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIXPublication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. TMC-CAN-10-01Publication without faculty affiliation
- New players on the antiplatelet therapy chequerboard - what can we expect?2010 | First Faculty of Medicine, Third Faculty of Medicine
- News in secondary prevention of atherothrombotic events - focus on ticagrelor2016 | First Faculty of Medicine
- Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial2019 | Publication without faculty affiliation
- Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction2015 | Second Faculty of Medicine